OHSU Scientists First to Create Primate Embryonic Stem Cells
News Nov 15, 2007
Researchers at Oregon Health & Science University’s Oregon National Primate Research Center have made a breakthrough in efforts to develop human stem cell therapies that may be used to combat numerous devastating diseases.
For the first time, scientists have derived embryonic stem cells by reprogramming of genetic material from skin cells while studying rhesus macaque monkeys. The breakthrough follows several previously unsuccessful attempts by the OHSU-based team and other scientific teams worldwide. The results of the work are released online by the scientific journal Nature. The work will also be published in next week’s edition of the journal.
Prior to the OHSU team’s recent success in a species closely related to humans, scientists worldwide have isolated stem cells only in mice using a technique called somatic cell nuclear transfer. The method involves transplanting the nucleus of the cell, containing an individual’s DNA, to an egg cell which has had its genetic material removed. For various reasons and despite numerous attempts, previous efforts to use the SCNT technology to clone stem cells in primates have failed repeatedly.
“Many scientists believe that embryonic stem cells hold great promise for treating a variety of diseases including Parkinson’s disease, multiple sclerosis, cardiac disease and spinal cord injuries,” explained Shoukhrat Mitalipov, Ph.D., director of the OHSU-based research team and an assistant scientist in the Division of Reproductive Sciences at ONPRC, the Oregon Stem Cell Center and the department of Obstetrics and Gynecology of Oregon Health & Science University. Don Wolf, Ph.D. of the primate center also played a significant role in the research.
“Using our advanced methods, it is conceivable that years from now, patients could receive therapeutic embryonic stem cells developed from their very own cells meaning that there would be no concerns about transplant rejection. Another noteworthy aspect of this research is that it does not involve the use of fertilized embryos, a topic which has been the source of a significant ethical debate in this country.”
The Munroe-Meyer Institute and the Whitehead Institute for Biomedical Research collaborated with OHSU to conduct this research. The studies were funded by the Oregon National Primate Research Center, the National Center for Research Resources, and the National Institute of Neurological Disorders and Stroke, both components of the National Institutes of Health.
“This advance at the Oregon National Primate Research Center builds on studies supported over several years by the NCRR aimed at understanding the basic biology of stem cells and at developing methods to investigate non human primate models of disease,” said John D. Harding, Ph.D., NCRR's Director of Primate Resources. “These studies have great potential to accelerate progress in the field of regenerative medicine.”
“While development of the stem cell lines required hundreds of attempts, this research proves it can be done and will likely lead to refinements which will make the process more efficient and lead to a higher success rate,” explained Mitalipov. “This is the next step for our research team as other scientists continue to investigate the promise of stem cell therapies.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.